BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN),European Respiratory Journal

当前位置： X-MOL 学术 › Eur. Respir. J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

BAY 2253651 for the treatment of obstructive sleep apnoea: a multicentre, double-blind, randomised controlled trial (SANDMAN)
European Respiratory Journal ( IF 16.6 ) Pub Date : 2021-11-18 , DOI: 10.1183/13993003.01937-2021
Thomas Gaisl ₁ , Chris D Turnbull _{2,

3} , Gerrit Weimann ₄ , Sigrun Unger ₅ , Rudolf Finger ₅ , Charles Xing ₆ , Peter A Cistulli _{7,

8} , Sophie West ₉ , Alan K I Chiang ₁₀ , Danny J Eckert ₁₁ , John R Stradling _{2,

3} , Malcolm Kohler _{12,

13}

Affiliation

Sleep Disorders Center and Pulmonary Division, University Hospital Zurich, Zurich, Switzerland.
National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Clinical Experimentation, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
Clinical Operations, Pharma Research Center, Bayer Pharma, Wuppertal, Germany.
Global Development, Bayer Healthcare Company, Beijing, China.
Sleep Research Group, Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Dept of Respiratory and Sleep Medicine, Centre for Sleep Health and Research, Royal North Shore Hospital, Sydney, Australia.
Newcastle Regional Sleep Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Neuroscience Research Australia (NeuRA), Sydney, Australia.
Adelaide Institute for Sleep Health, Flinders health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Sleep Disorders Center and Pulmonary Division, University Hospital Zurich, Zurich, Switzerland
Zurich Center for Interdisciplinary Sleep Research, University of Zurich, Zurich, Switzerland.

For obstructive sleep apnoea (OSA), few mechanical treatment options are available and no pharmacotherapy is approved [1–3]. However, safe and efficacious pharmacotherapy would have substantial appeal for many people with OSA.

中文翻译：